{"id":"NCT03930186","sponsor":"Amgen","briefTitle":"A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy","officialTitle":"A Phase 3b, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-17","primaryCompletion":"2020-05-08","completion":"2020-09-25","firstPosted":"2019-04-29","resultsPosted":"2022-01-20","lastUpdate":"2022-01-20"},"enrollment":152,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Apremilast","otherNames":["CC-10004","OtezlaÂ®"]},{"type":"DRUG","name":"Topical Therapy","otherNames":[]}],"arms":[{"label":"Apremilast","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to assess the efficacy and safety of the combination of apremilast plus topical therapies for the treatment of adults with plaque psoriasis who have not achieved an adequate response with topicals alone.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved an sPGA Score of Clear (0) or Almost Clear (1) at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Apremilast","deltaMin":43.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":56,"countries":["Germany","Japan"]},"refs":{"pmids":["38801606","35689737"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":152},"commonTop":["Diarrhoea","Nausea","Nasopharyngitis","Faeces soft","Headache"]}}